Vistagen therapeutics

What's Happening With Vistagen Therapeutics Inc Stock Today? Vistagen Therapeutics Inc (VTGN) stock is trading at $1.16 as of 3:06 PM on Friday, Jun 3, a drop of -$0.01, or -0.85% from the previous closing price of $1.17. The stock has traded between $1.14 and $1.20 so far today. Volume today is light. So far 481,757 shares have traded compared ...VistaGen Therapeutics, Inc today reported its financial results for the fiscal year 2022 second quarter ended September 30, 2021 and provided a review of the Company's recent accomplishments. VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021. 11/4/2021SOUTH SAN FRANCISCO, June 02, 2022--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform ... VistaGen Therapeutics Inc. (VTGN) full year performance was -72.24%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -73.67% during the 52-week period from high price, and 4. ...VTGN Intrinsic Value: Projected FCF as of today (July 18, 2022) is $-0.97. In depth view into VistaGen Therapeutics Intrinsic Value: Projected FCF explanation, calculation, historical data and moreJul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. Vistagen Therapeutics Inc ( VTGN) is around the top of the Healthcare sector according to InvestorsObserver . VTGN received an overall rating of 39, which means that it scores higher than 39% of stocks. Additionally, Vistagen Therapeutics Inc scored a 76 in the Healthcare sector, ranking it higher than 76% of stocks in that sector.VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.15 per share a year ago.VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Jun 29, 2021 · SOUTH SAN FRANCISCO, Calif., June 29, 2021 - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for ... SOUTH SAN FRANCISCO, Calif., June 17, 2022--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the ...Contact Email [email protected] Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101 ... Jun 29, 2021 · SOUTH SAN FRANCISCO, Calif., June 29, 2021 - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for ... 2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Jun 20, 2022 · About VistaGen Therapeutics . VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. A high-level overview of VistaGen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Jul 13, 2022 · To see how VistaGen Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VTGN stock’s performance was -6.12% in the latest trading, and -72.24% in the past year, while Iovance Biotherapeutics Inc. (IOVA) has traded 3.93% on the day and positioned -51.98% lower than it was a year ago. VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ...Jun 23, 2022 · VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update. Contact Email [email protected] Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101 ... The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts.VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business's stock in a transaction dated Tuesday, July 12th ...Jun 16, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ... The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. A high-level overview of VistaGen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and ... VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 14,150,000 shares, an increase of 30.7% from the May 31st total of 10,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 8.8% of the shares of the ...VistaGen Therapeutics Inc. (VTGN) full year performance was -72.24%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -73.67% during the 52-week period from high price, and 4. ...For VistaGen Therapeutics, a negative ROCE ratio of -0.26% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a ...2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. VistaGen Therapeutics, Inc. Aug 2009 - Jul 2022 13 years. United States CEO VistaGen Therapeutics Jun 1998 - Aug 2009 11 years 3 months. CSO Progenitor, Inc 1993 ...Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. On June 23, VistaGen Therapeutics is reporting earnings from the most recent quarter. Analysts predict VistaGen Therapeutics will report losses per share of $0.058. Track VistaGen Therapeutics ...Shares of VistaGen Therapeutics ( VTGN -9.60%) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy ...Jun 20, 2022 · About VistaGen Therapeutics . VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for CNS diseases and disorders where current treatments are inadequate, resulting in high ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three CNS drug candidates has a differentiated profile and therapeutic potential in ...VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a ...About VistaGen Therapeutics Inc. VistaGen is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety ...SOUTH SAN FRANCISCO, Calif., June 17, 2022--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the ...SOUTH SAN FRANCISCO, Calif., June 17, 2022--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the ...On June 23, 2022, VistaGen Therapeutics, Inc. (the "Company") issued a press release to announce the Company's financial results for its fiscal year ended March 31, 2022. A copy of the press ...Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. Jun 17, 2022 · VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression ... VistaGen Therapeutics (NASDAQ:VTGN) is a small-cap biotech company currently possessing 3 drug candidates in clinical trials for various psychiatric indications. Out of the 3 candidates, both ...The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. The VistaGen Therapeutics Inc stock price fell by -9.60% on the last day (Friday, 15th Jul 2022) from $0.86 to $0.78. and has now fallen 3 days in a row. During the day the stock fluctuated 17.80% from a day low at $0.77 to a day high of $0.91. The price has fallen in 6 of the last 10 days and is down by -11.35% for this period.For VistaGen Therapeutics, a negative ROCE ratio of -0.26% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.15 per share a year ago.VistaGen Therapeutics Inc. analyst estimates, including VTGN earnings per share estimates and analyst recommendations.VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California, the "Birthplace of ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for ...VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation ...On June 23, VistaGen Therapeutics is reporting earnings from the most recent quarter. Analysts predict VistaGen Therapeutics will report losses per share of $0.058. Track VistaGen Therapeutics ...VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for CNS diseases and disorders where current treatments are inadequate, resulting in high ...About VistaGen Therapeutics Inc. VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of ...About VistaGen VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and ...VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 14,150,000 shares, an increase of 30.7% from the May 31st total of 10,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 8.8% of the shares of the ...Apr 22, 2022 · Vistagen Therapeutics Inc ( VTGN) is around the top of the Healthcare sector according to InvestorsObserver . VTGN received an overall rating of 39, which means that it scores higher than 39% of stocks. Additionally, Vistagen Therapeutics Inc scored a 76 in the Healthcare sector, ranking it higher than 76% of stocks in that sector. VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all ...Jun 17, 2022 · VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression ... VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a ...VistaGen Therapeutics Stock Performance NASDAQ VTGN opened at $0.78 on Friday. The business has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.29.About VistaGen VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and ...VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation ...For VistaGen Therapeutics, a negative ROCE ratio of -0.26% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.Apr 21, 2022 · SOUTH SAN FRANCISCO, Calif., April 21, 2022-VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present ... For VistaGen Therapeutics, a negative ROCE ratio of -0.26% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for ...The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Jul 18, 2022 · VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ... VistaGen Therapeutics Stock Performance NASDAQ VTGN opened at $0.78 on Friday. The business has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.29.VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.20 per share a year ago.VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates ...Jun 24, 2022 · On June 23, 2022, VistaGen Therapeutics, Inc. (the "Company") issued a press release to announce the Company's financial results for its fiscal year ended March 31, 2022. A copy of the press ... VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 14,150,000 shares, an increase of 30.7% from the May 31st total of 10,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 8.8% of the shares of the ...The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. VistaGen Therapeutics Inc.'s market cap currently stands at around $189.43 million, with investors looking forward to this quarter's earnings report slated for Feb 09, 2022 - Feb 14, 2022. Analysts project the company's earnings per share (EPS) to be -$0.06, which has seen fiscal year 2022 EPS growth forecast to increase to -$0.22 and ...VistaGen Therapeutics Inc.'s market cap currently stands at around $189.43 million, with investors looking forward to this quarter's earnings report slated for Feb 09, 2022 - Feb 14, 2022. Analysts project the company's earnings per share (EPS) to be -$0.06, which has seen fiscal year 2022 EPS growth forecast to increase to -$0.22 and ...Vistagen Therapeutics Inc stock is higher by 307.58% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives VTGN stock a score of 82 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 85.Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. Industry stock comparison between VistaGen Therapeutics and NovaBay PharmaceuticalsSOUTH SAN FRANCISCO, June 02, 2022--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform ... Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. VistaGen Therapeutics Inc. (VTGN) full year performance was -72.24%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -73.67% during the 52-week period from high price, and 4. ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ...Jun 17, 2022 · VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression ... VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a ...VistaGen Therapeutics Inc. analyst estimates, including VTGN earnings per share estimates and analyst recommendations.VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for CNS diseases and disorders where current treatments are inadequate, resulting in high ...VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...Jun 03, 2022 · What's Happening With Vistagen Therapeutics Inc Stock Today? Vistagen Therapeutics Inc (VTGN) stock is trading at $1.16 as of 3:06 PM on Friday, Jun 3, a drop of -$0.01, or -0.85% from the previous closing price of $1.17. The stock has traded between $1.14 and $1.20 so far today. Volume today is light. So far 481,757 shares have traded compared ... VistaGen Therapeutics Inc. (VTGN) full year performance was -72.24%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -73.67% during the 52-week period from high price, and 4. ...Jun 23, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets: Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. On June 23, VistaGen Therapeutics is reporting earnings from the most recent quarter. Analysts predict VistaGen Therapeutics will report losses per share of $0.058. Track VistaGen Therapeutics ...Jul 18, 2022 · VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ... VistaGen Therapeutics Company Profile . VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset ...Jun 03, 2022 · What's Happening With Vistagen Therapeutics Inc Stock Today? Vistagen Therapeutics Inc (VTGN) stock is trading at $1.16 as of 3:06 PM on Friday, Jun 3, a drop of -$0.01, or -0.85% from the previous closing price of $1.17. The stock has traded between $1.14 and $1.20 so far today. Volume today is light. So far 481,757 shares have traded compared ... Contact Email [email protected] Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101 ... Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. Real-time trade and investing ideas on VistaGen Therapeutics Inc VTGN from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. VistaGen Therapeutics Inc 0.78 0.08 (9.60%) Watch.The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Jul 12, 2022 · A high-level overview of VistaGen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 14,150,000 shares, an increase of 30.7% from the May 31st total of 10,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 8.8% of the shares of the ...VistaGen Therapeutics, Inc. (NASDAQ:NASDAQ:VTGN) Q4 2022 Earnings Conference Call June 23, 2022 05:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn...VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a ...VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.Jun 16, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ... VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ...Apr 22, 2022 · Vistagen Therapeutics Inc ( VTGN) is around the top of the Healthcare sector according to InvestorsObserver . VTGN received an overall rating of 39, which means that it scores higher than 39% of stocks. Additionally, Vistagen Therapeutics Inc scored a 76 in the Healthcare sector, ranking it higher than 76% of stocks in that sector. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses. Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacologyhighlight fundamentally differentiated mechanism of action for PH94B. These preclinical data demonstrate that intranasal radiolabelled-PH94B is largely confined ...2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. VistaGen Therapeutics Stock Performance NASDAQ VTGN opened at $0.78 on Friday. The business has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.29.VistaGen Therapeutics is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people around the world. ...Shares of VistaGen Therapeutics ( VTGN -9.60%) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy ...Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. The Investor Relations website contains information about VistaGen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for ...Jul 13, 2022 · To see how VistaGen Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VTGN stock’s performance was -6.12% in the latest trading, and -72.24% in the past year, while Iovance Biotherapeutics Inc. (IOVA) has traded 3.93% on the day and positioned -51.98% lower than it was a year ago. Feb 07, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday ... VistaGen Therapeutics, Inc. Aug 2009 - Jul 2022 13 years. United States CEO VistaGen Therapeutics Jun 1998 - Aug 2009 11 years 3 months. CSO Progenitor, Inc 1993 ...VistaGen Therapeutics (NASDAQ:VTGN) is a small-cap biotech company currently possessing 3 drug candidates in clinical trials for various psychiatric indications. Out of the 3 candidates, both ...2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. Jul 12, 2022 · SOUTH SAN FRANCISCO, Calif., July 12, 2022--VistaGen's CEO will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy at the Concordia Summit to discuss the ongoing mental health crisis. Feb 07, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday ... VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.20 per share a year ago.For VistaGen Therapeutics, a negative ROCE ratio of -0.26% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.Jun 17, 2022 · VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report ... VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California, the "Birthplace of ...Jun 17, 2022 · About VistaGen VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with ... 2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. On June 23, 2022, VistaGen Therapeutics, Inc. (the "Company") issued a press release to announce the Company's financial results for its fiscal year ended March 31, 2022. A copy of the press ...Apr 21, 2022 · SOUTH SAN FRANCISCO, Calif., April 21, 2022-VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present ... VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Rating) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 14,150,000 shares, an increase of 30.7% from the May 31st total of 10,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 8.8% of the shares of the ...VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase ...Event: VistaGen Therapeutics Fiscal Year 2022 Financial Results Conference Call. Date: Thursday, June 23, 2022. Time: 2:00 pm Pacific Time (5:00 pm Eastern Time) US Dial-in (Toll Free): 1-877-407 ...2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. About VistaGen Therapeutics Inc. VistaGen is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety ...Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Jul 12, 2022 · A high-level overview of VistaGen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. Jul 18, 2022 · VistaGen Therapeutics Inc. (VTGN) is priced at $0.78 after the most recent trading session. At the very opening of the session, the stock price was $0.9085 and reached a high price of $0.9085, prior to closing the session it reached the value of $0.86. The stock touched a low price of $0.7712.Recently in News on July 12, 2022, VistaGen CEO ... Jun 17, 2022 · VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report ... VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. Analyst Price Target on VTGN. Based on 3 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 651.96% change from the last price of $0.93.2 days ago · VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business’s stock in a transaction dated Tuesday, July 12th. Jul 13, 2022 · VistaGen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1100 on 01/04/22, with the lowest value was $0.8332 for the same time period, recorded on 07/05/22. VistaGen Therapeutics is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people around the world. ...VTGN Intrinsic Value: Projected FCF as of today (July 18, 2022) is $-0.97. In depth view into VistaGen Therapeutics Intrinsic Value: Projected FCF explanation, calculation, historical data and moreVistaGen Therapeutics Inc. (VTGN) full year performance was -72.24%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -73.67% during the 52-week period from high price, and 4. ... reigns definition in englishsocratic questioning in the classroombest prowler skinsony a7siii recording formats Ost_